2021
Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining Their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA)
PSÁR, Robert, Ondřej URBAN, Marie ČERNÁ, Tomáš ROHAN, Martin HILL et. al.Základní údaje
Originální název
Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining Their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA)
Autoři
PSÁR, Robert (203 Česká republika, garant), Ondřej URBAN (203 Česká republika), Marie ČERNÁ (203 Česká republika), Tomáš ROHAN (203 Česká republika, domácí) a Martin HILL (203 Česká republika)
Vydání
Diagnostics, Švýcarsko, MDPI, 2021, 2075-4418
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30224 Radiology, nuclear medicine and medical imaging
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.992
Kód RIV
RIV/00216224:14110/21:00121876
Organizační jednotka
Lékařská fakulta
UT WoS
000653806900001
Klíčová slova anglicky
computed tomography; early diagnosis; endoscopic ultrasound-guided fine needle aspiration; isoattenuation; pancreatic carcinoma
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 8. 2021 08:28, Mgr. Tereza Miškechová
Anotace
V originále
(1) Background. The aim was to define typical features of isoattenuating pancreatic carcinomas on computed tomography (CT) and endosonography and determine the yield of fine-needle aspiration endosonography (EUS-FNA) in their diagnosis. (2) Methods. One hundred and seventy-three patients with pancreatic carcinomas underwent multiphase contrast-enhanced CT followed by EUS-FNA at the time of diagnosis. Secondary signs on CT, size and location on EUS, and the yield of EUS-FNA in isoattenuating and hypoattenuating pancreatic cancer, were evaluated. (3) Results. Isoattenuating pancreatic carcinomas occurred in 12.1% of patients. Secondary signs of isoattenuating pancreatic carcinomas on CT were present in 95.2% cases and included dilatation of the pancreatic duct and/or the common bile duct (85.7%), interruption of the pancreatic duct (76.2%), abnormal pancreatic contour (33.3%), and atrophy of the distal parenchyma (9.5%) Compared to hypoattenuating pancreatic carcinomas, isoattenuating carcinomas were more often localized in the pancreatic head (100% vs. 59.2%; p < 0.001). In ROC (receiver operating characteristic) analysis, the optimal cut-off value for the size of isoattenuating carcinomas on EUS was <= 25 mm (AUC = 0.898). The sensitivity of EUS-FNA in confirmation of isoattenuating and hypoattenuating pancreatic cancer were 90.5% and 92.8% (p = 0.886). (4) Conclusions. Isoattenuating pancreatic head carcinoma can be revealed by indirect signs on CT and confirmed with high sensitivity by EUS-FNA.